CVKD

Cadrenal Therapeutics, Inc.

8 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMay 7

Company issued a going concern warning due to insufficient cash to meet 12-month obligations.

margin compression

90%

neutralMay 7

Raised $2.5 million through a warrant inducement to extend operational runway.

capital raise

60%

bullishMay 7

Acquired assets from Veralox and eXIthera to expand the 12-LOX and FXIa inhibitor pipeline.

acquisition

70%

bullishMay 7

Secured FDA alignment on Phase 3 pivotal trial design for lead asset CAD-1005.

regulatory action

80%

bearishMar 31

Severe cash shortage and 'substantial doubt' about going concern status necessitate immediate dilutive funding.

dilution risk

90%

bullishMar 31

Completed EOP2 meeting with FDA and clarified registrational path for Phase 3 pivotal trial of CAD-1005.

regulatory action

70%

bearishMar 31

Expiration of core tecarfarin patents removes market exclusivity and threatens future margins.

margin compression

60%

Filing History

10-QMay 7, 2026

The latest 10-Q paints a picture of a company with high-value intellectual property but critical financial instability. The successful FDA alignment for CAD-1005 provides the 'what' and 'how' for success, but the balance sheet questions the 'if.' While the reduction in quarterly burn is a positive signal, it is overshadowed by the fact that the company cannot fund its own Phase 3 trials without significant external capital. Investors are now faced with a binary trade-off. The upside is a first-in-class therapy for a deadly disorder with orphan drug exclusivity. The downside is a classic biotech 'death spiral' where the need for cash leads to continuous dilution and potential delisting. The critical window for Cadrenal is the next six months, during which it must secure a strategic partner or a major financing round to bridge the gap to clinical execution.

10-KMar 31, 2026

Cadrenal Therapeutics is currently a high-risk, high-reward binary play centered on the transition to a Phase 3 pivotal trial for CAD-1005. The company has successfully pivoted its strategic focus and aligned management incentives through significant insider ownership. However, this operational discipline is currently overshadowed by a dire balance sheet and a looming cash crunch that threatens to derail clinical timelines. Investors are essentially weighing the potential of a first-in-class HIT treatment against the immediate risk of insolvency or massive shareholder dilution. While the regulatory designations provide a tailwind, the lack of current IP protection for tecarfarin and the missed primary endpoint in early CAD-1005 trials suggest that the path to the projected $825 million in peak revenue is fraught with significant clinical and legal hurdles.